- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03916614
Relief of Symptoms of Post-traumatic Stress for Victims of Gun Violence
April 13, 2022 updated by: Yale University
Relief of Symptoms of Post-traumatic Stress for Victims of Gun Violence:
To test the hypothesis that adult individuals who are victims of gun violence will have decreased symptoms of post-traumatic stress after an individual-level intervention with the Screening and Tool for Awareness and Relief of Trauma (START).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In response to the lack of targeted mental health intervention for gunshot wound survivors, the Screening and Tool for Awareness and Relief of Trauma (START) was developed for patients that come from communities with sustained and persistent trauma.
It consists of six screening questions adapted from the validated Primary Care PTSD Screen,[30] with input from focus groups, surveys and in-depth interviews with victims of violence and in particular, boys and young men of color.
START has been shown to be effective at decreasing symptoms of PTSD in a one-month follow-up, but it has not been piloted on recently injured victims of gun violence specifically nor has it been tested in a randomized control trial design.
A better understanding of the utility of this tool and others like it in victims of violent crime for relief of symptoms of post-traumatic stress and prevention of PTSD would contribute to the larger body of literature on PTSD prevention for victims of gun violence while simultaneously addressing a major need in this community.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale New Haven Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Survivors of gunshot wound presenting to the Emergency room and/or admitted as inpatient that are eligible for the Violence Prevention and Outreach Program (VPOP).
Exclusion Criteria:
- Patients with severe traumatic brain injury
- Children under the age of 18
- Patients otherwise unable to give consent
- Non-English speaking patients
- Victims of sexual assault
- Patients with history of a severe mental illness and/or those already undergoing treatment for a mental illness by a licensed professional.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: START treatment
Participants randomized into the treatment arm will receive the START intervention as described above alongside usual care from the VPOP staff
|
The Screening and Tool for Awareness and Relief of Trauma (START) was developed for patients that come from communities with sustained and persistent trauma.
It consists of six screening questions adapted from the validated Primary Care PTSD Screen,[30] with input from focus groups, surveys and in-depth interviews with victims of violence.
The full START intervention requires 30-45 minutes of structured conversation at the end of which the participant leaves with a better understanding of trauma symptoms as well as on-the-spot instruction on a set of techniques designed to alleviate the symptoms of PTSD.
Based on the results of their screening, the participant will be offered up to four techniques to alleviate their symptoms
|
|
ACTIVE_COMPARATOR: standard of care
Those randomized to the control arm will receive the usual screening for PTSD and referral for outpatient services if warranted as well as usual care from VPOP staff.
|
Screening for PTSD and referral for outpatient services if warranted as well as usual care from Violence Prevention and Outreach Program (VPOP) staff.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PTSD evaluation
Time Frame: baseline
|
Post Traumatic Stress Disorder Checklist - Civilian Version (PCL-C)
|
baseline
|
|
Change in PTSD evaluation test scores
Time Frame: 12 weeks
|
Post Traumatic Stress Disorder Checklist - Civilian Version (PCL-C) A decrease in PCL-C score greater than or equal to 5 points relative to controls.
|
12 weeks
|
|
Change PTSD evaluation test scores
Time Frame: 6 months
|
Post Traumatic Stress Disorder Checklist - Civilian Version (PCL-C) A decrease in PCL-C score greater than or equal to 5 points relative to controls.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: James Dodington, MD, Yale University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 1, 2020
Primary Completion (ACTUAL)
January 1, 2022
Study Completion (ACTUAL)
January 1, 2022
Study Registration Dates
First Submitted
April 11, 2019
First Submitted That Met QC Criteria
April 11, 2019
First Posted (ACTUAL)
April 16, 2019
Study Record Updates
Last Update Posted (ACTUAL)
April 14, 2022
Last Update Submitted That Met QC Criteria
April 13, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000025580
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PTSD
-
University of PittsburghCompletedPTSD | Non PTSDUnited States
-
COMPASS PathwaysNot yet recruitingPTSD | PTSD, Post Traumatic Stress Disorder | PTSD Symptoms | PTSD - Post Traumatic Stress Disorder
-
Valhalla Project NiagaraRecruiting
-
York UniversityRecruiting
-
VA Office of Research and DevelopmentCompleted
-
Tonix Pharmaceuticals, Inc.Withdrawn
-
University of Wisconsin, MadisonCompleted
-
University of PennsylvaniaUniversity of TexasCompleted
-
Johns Hopkins UniversitySchool of Biomedical Sciences, University of Otago, Dunedin, New Zealand; D...Completed
Clinical Trials on Screening Tool for Relief of Trauma (START)
-
Universidade Cidade de Sao PauloUnknownLow Back Pain
-
Wolfson Medical CenterCompleted
-
The University of Texas Health Science Center,...National Institute on Aging (NIA)Recruiting
-
Lisa RicharsonCompleted
-
Mayo ClinicCompletedAtrial FibrillationUnited States
-
Picterus ASNorwegian University of Science and TechnologyTerminatedNeonatal JaundiceUganda
-
Queen Mary University of LondonImperial College London; University College, London; City, University of LondonCompleted
-
Hospices Civils de LyonRecruitingSwallowing Disorder | Sarcopanic DysphagiaFrance
-
University of UtahCompletedLung Neoplasms | Early Detection of CancerUnited States
-
Barcelona Institute for Global HealthUniversidad de Granada; Consorci d'Atenció Primària de Salut de l'Eixample; Hospital... and other collaboratorsCompletedHepatitis B | Hepatitis C | Tuberculosis | Hiv | Chagas Disease | Schistosomiasis | Strongyloidiasis | Female Genital Mutilation Type I Status | Female Genital Mutilation Type II Status | Female Genital Mutilation Type III StatusSpain